Page 71 - CIBERBBN-2015-eng

Research groups
Most relevant scientific articles
MORENO M.J., BOSCH R., DIEGUEZ-GONZáLEZ R., NOVELLI S., MOZOS A., GALLARDO A. ET AL. CXCR4 expression en- hances diffuse large B cell lymphoma dissemination and decreases patient survival. Journal of Pathology. 2015;235(3):445-455.
UNZUETA U., CESPEDES M.V., VAZQUEZ E., FERRER-MIRALLES N., MANGUES R., VILLAVERDE A. Towards protein-based vi- ral mimetics for cancer therapies. Trends in Biotechnolo- gy. 2015;33(5):253-258.
RUEDA F., CESPEDES M.V., CONCHILLO-SOLE O., SáNCHEZ-CHARDI A., SERAS-FRANZOSO J., CUBARSI R. ET AL. Bottom-Up Instructive Quality Control in the Biofabrication of Smart Protein Materials. Advanced Materials. 2015.
BLAY J.-Y., PAPAI Z., TOLCHER A.W., ITALIANO A., CUPISSOL D., LóPEZ-POUSA A. ET AL. Ombrabulin plus cisplatin ver- sus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: A randomised, double-blind,
PAVON M.A., PARRENO M., TELLEZ-GABRIEL M., LEON X., ARROYO-SOLERA I., LóPEZ M. ET AL. CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carci- noma. Head and Neck. 2015.
Highlights
During this year, we have raised additional funding for the development of the CIBER-BBN Intramural project Nanomets, having obtained an Integrated Project of Excellence from the Instituto de Salud Carlos III (PIE/00028) and a Coordinated Project from the FIS (PI15/00378). We have also obtained an industrial transference project (2014 PROD 00055) that has allowed starting a negotiation for a possible license agreement involving the WO2012/095527 patent that protects the nanoconjugate developed in the Nanomets project, in which CIBER-BBN is a partner. We have renew our recognition as a consolidated research group (2014-SGR-1041) and have bee accepted as members of the EU COST Action CM1106 working on drug resistance and cancer stem cells. The CIBER-BBN Nanotoxicology Unit, that our group coordinates, which is integrated in the Nanbiosis Network has been recognized as a Singular Infrastructure (ICTS) and obtained funding for its promotion from MINECO (SAF2015-69388).
placebo-controlled, phase 3 trial. The Lancet Oncology. 2015;16(5):531-540.
Our group has incorporate a new Miguel Servet Researcher (CP/00163), who will direct a new project on a nanoconjugate for the treatment of pancreatic carcinoma, a new Sara Borrell postdoctoral researcher (CD14/00055) and a new technician for giving support to the Nanotoxicology Platform (PTA2013-8426-I). We have also incorporated to the Group two new pre-doctoral students and a Specialist in Surgery from the Hospital de Sant Pau to carry out their thesis project. Over this year, we have developed a new colorectal carcinoma model with enhanced metastatic efficiency. We have used this model to demonstrate a selective biodistribution to primary tumor and metastases of the nanoconjugate developed in the Nanomets intramural project, and we have also demonstrated a potent antimetastatic effect especially regarding liver, lung and peritoneal foci.
Institution: Instituto de Investigación del Hospital de la Santa Creu i Sant Pau
Contact: Pabellón del Convento, 1er. piso. Hospital de la Sant Creu i Sant Pau. Sant Antoni M. Claret, 167 08025 Barcelona · Tel.: 93 553 79 18 · E.mail: [email protected] · Web: http://www.iibsantpau.cat/
CIBER-BBN I Annual report 2015 I 71